

Date: 2009-Dec-21

To: Centre Representatives
 Ethics Representatives
 Contact Clinical Research Associates

From: Anna Sadura, Trial Management, NCIC Clinical Trials Group

**RE: PERMANENT TRIAL CLOSURE NOTICE FOR
 PHASE I/II/III NCIC CTG LED STUDIES**

Dear Participants,

We are writing today to inform you of the results of our annual Permanent Trial Closure Assessment. This annual process includes two components: assessment of trials led by NCIC CTG and assessment of trials led by intergroup collaborators. This letter addresses the first of these components. We have identified the following NCIC CTG-led trials that are complete and no longer require action. Please find these trials listed below. "No longer require action" includes cessation of all patient follow-up for trial purposes, completion of Case Report Forms and obtaining of annual REB re-approvals. We are hopeful that the permanent closure of trials that have met all study endpoints and that no longer warrant data collection will reduce the workload for participating centres.

Effective immediately, data submission and REB approval for the following NCIC CTG- led trials is no longer required:

<i>Disease Site</i>	<i>Trial Code</i>	<i>Contact</i>
Breast	MA.15*, MA.17B	Michael Palmer mpalmer@ctg.queensu.ca
Gynecology	EN.5	Monica Bacon m Bacon@ctg.queensu.ca
Hematology	CL.2 MY.7	Anna Sadura asadura@ctg.queensu.ca Marina Djurfeldt mdjurfeldt@ctg.queensu.ca
Lung	BR.8, BR.9 BR.10	Christine Bertrim cbertrim@ctg.queensu.ca Barb Graham bgraham@ctg.queensu.ca
IND	50, 68, 70, 76, 77, 81, 84, 85, 101, 102, 105, 106, 107, 108, 109, 114, 115, 119, 128, 133, 137, 149, 150, 152, 154, 156, 157	Jean Powers jpowers@ctg.queensu.ca

**** A separate letter will follow outlining trial specific details of permanent closure.***

In addition, NCIC CTG will be altering the conduct of MA.17. Because the MA.17 and MA.17R trials are intimately linked, the details of this process will be described in a trial-specific notice that is to follow. Please do NOT include MA.17 among the list of trials for closure, but instead follow the instructions that will be detailed in the trial-specific notice that is to follow.

Health Canada, NCI US, intergroup collaborators and industry partners have been notified of these final trial closures where applicable. Please notify your REB of any outstanding ethics documents for the applicable trials above and of the final completion of these trials. A copy of this notification must be kept on file at your centre for auditing purposes. Please note that this memorandum supersedes any protocol instructions requiring the continued follow-up of patients and submission of data.

Please note that although these trials are permanently closed, trial documents must still be retained. NCIC CTG will continue to notify participating centres when trial related records no longer need to be retained in accordance with applicable regulations. Please visit the following web site for further information: <http://www.ctg.queensu.ca/private/ethics/RecordsRetention.pdf>

Shortly, we will be circulating a second notice that addresses our annual review of intergroup trials that can be closed to further activity.

Yours sincerely,

A handwritten signature in black ink, appearing to read "Anura Asadura". The signature is fluid and cursive, with the first name "Anura" being more prominent than the last name "Asadura".

Manager, Trial Conduct
NCIC CTG Clinical Trials Group
asadura@ctg.queensu.ca